The First Symposium on Research and Development of Small Molecule Drugs
2024year4month25 - 26OnInnoXBio2024The First Small Molecule Drug Research and Development Forum was successfully held in Nanjing. The conference focused on biomarkers and translational medicine, 'undruggable' targets, the development of small molecule drugs for tumors and non-tumors,ADCCoupling technology,License In and OutTopic-based, eight thematic forums are launched, inviting70+Guest Speakers1,000+Industry experts, exploring together and seeking common development for the industry.
Frost & SullivanFrost & SullivanChen Zhenrong, consulting director of Frost & Sullivan's Life Sciences Practice in Greater China, was invited to attend the event and participate in “ADCThe special forum on "Coupling Technology and Drug Development", and onADCDelivered a speech on "The Global Market Structure and Trends of Pharmaceuticals".
Consulting Director, Life Sciences Business Unit, Frost & Sullivan Greater China Region Chen Zhenrong
Chen Zhenrong introduced, globallyADCPrimary market financing in the pharmaceutical sector2020The year saw a surge, with capital inflows driving industrial development. At the same time,ADCdrugLicense-out of the MainlandWith frequent incidents and a phenomenon-level impact,2023Chinese drugs inLicense-out of the MainlandThe total down payment exceeds for the first timeIPO listingFundraising. GloballyADCLooking at the clinical R&D situation in the field,ADCThe R&D in the field is accelerating, new research results are emerging continuously. After security verification, effectiveness has become a core competitiveness, and there is a high richness of innovative targets. Currently, China has becomeADCAn important innovation source in the field, with many enterprises deploying efforts here. However, currently, there is a high degree of homogenization among targets, leading to fierce competition.
Source: Analysis by Frost & Sullivan
Chen Zhenrong pointed out,ADCThe development involves antibodies, conjugates, payloads, and coupling technologies, presenting many challenges in research and production. With the development of dual-target antibodies, the optimization of conjugates, the emergence of protein degrading agents and other payloads, and the adjustment of site-specific quantitative coupling technologies,ADCThe safety and effectiveness of drugs will be enhanced. New generationADCThe product will possess a larger therapeutic window, superior specificity and cytotoxicity, as well as updated treatment mechanisms, overallADCThe pharmaceutical market is expected to continue growing, with broad market prospects.
More exciting moments from the event arena
About Frost & Sullivan's Life Sciences Practice
The Life Sciences Practice of Frost & Sullivan has professional analytical capabilities and extensive project experience in the field of life sciences. Leveraging Frost & Sullivan's global think tank resources and cross-industry business development platform in Greater China, the Life Sciences Practice has unique core advantages in investment and financing services for the life science industry. The Life Sciences Practice has a wide range of corporate clients in China and in the past20In the year, a vast customer network was established, accumulating extensive project experience in various subfields of life sciences.
Project types include Knowledge Center projects (in-depth content, promotional activities).Pre-IPO financingprojectDCF modelValuation, Business Plan Services),IPO listingWe provide listed projects (industry consulting, clinical audits, fundraising writing), market research, market value management, strategic consulting, etc. We also cooperate with well-known domestic and international information platforms and investment and financing institutions to provide one-stop solutions for enterprises in specialized fields such as pharmaceuticals and medical devices, attracting widespread attention from investors.
